Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 78,553 Shares

Natera, Inc. (NASDAQ:NTRAGet Free Report) CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

  • On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total value of $692,226.48.
  • On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $468,111.60.

Natera Stock Up 2.7 %

NTRA stock opened at $171.93 on Thursday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average price of $165.35 and a two-hundred day moving average price of $135.41. The company has a market cap of $22.70 billion, a price-to-earnings ratio of -97.69 and a beta of 1.65. Natera, Inc. has a twelve month low of $62.96 and a twelve month high of $183.00.

Natera (NASDAQ:NTRAGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the firm posted ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis. Analysts anticipate that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NTRA shares. Morgan Stanley increased their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $160.63.

Get Our Latest Stock Analysis on Natera

Institutional Trading of Natera

A number of hedge funds have recently made changes to their positions in NTRA. Dimensional Fund Advisors LP lifted its position in shares of Natera by 35.6% in the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock valued at $28,680,000 after buying an additional 69,523 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Natera in the second quarter valued at approximately $767,000. Amalgamated Bank lifted its position in shares of Natera by 6.0% in the second quarter. Amalgamated Bank now owns 7,590 shares of the medical research company’s stock valued at $822,000 after buying an additional 428 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Natera by 24.1% in the second quarter. XTX Topco Ltd now owns 4,846 shares of the medical research company’s stock valued at $525,000 after buying an additional 940 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its position in shares of Natera by 4,082.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,821 shares of the medical research company’s stock valued at $847,000 after buying an additional 7,634 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.